StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Citi Remains Bullish on Teva Pharma (TEVA) Amid Buffett Stake
February 15, 2018 7:18 AM
Citi reiterated a Buy rating and $24.00 price target on Teva Pharma (NYSE: TEVA) following the company's 13-F filing. Berkshire ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
The Oracle of Omaha Goes Value Shopping in the Value Pharmaceutical Bin with Teva (TEVA)
February 15, 2018 12:26 PM
Teva (TEVA) volatility flat into Berkshire Hathaway (BRK.A) disclosed a stake in the company
February 15, 2018 5:38 AM
After-Hours Stock Movers 02/14: (TRIP) (TEVA) (CSCO) Higher; (CDMO) (NTAP) (SPWR) Lower (more...)
February 14, 2018 6:07 PM
Berkshire buys Teva, feels IBM blues as Apple becomes top investment
February 14, 2018 4:50 PM
JANA Partners Enters Facebook (FB), Comcast (CMCSA) , Teva (TEVA) (more...) - 13F
February 14, 2018 4:24 PM
Buffett's Berkshire Hathaway Enters New Stake in Teva (TEVA), Adds to Apple (AAPL), BofA (BAC) (more...) - 13F
February 14, 2018 4:13 PM
Buffett's Berkshire enters Teva Pharma (NYSE: TEVA)
February 14, 2018 4:09 PM
Momenta/Sandoz Generic Copaxone Already Accounted for in Teva (TEVA) Estimates - Guggenheim
February 13, 2018 6:27 AM
